Business Context and Reporting Period
This Form 8-K Current Report was filed by aTyr Pharma, Inc. on July 30, 2018. The filing discloses two material events: the entry into a definitive lease amendment for the company's principal executive offices and the appointment of a new Chief Financial Officer.
Key Financial Metrics and Agreements
Lease Amendment (Item 1.01)
- Space Reduction: Leased space reduced by 3,986 square feet to a total of 20,508 square feet.
- Term Extension: Lease term extended to May 15, 2023 (four years beyond the previous termination date).
- Rent Structure: Base rent set at $3.90 per rentable square foot per month.
- Abatement: Full rent abatement for January and February 2019.
- Escalation: Annual rent increases of 3% starting one year after the effective date of the space surrender.
Executive Compensation (Item 5.02)
- Base Salary: $350,000 annually for the new CFO.
- Bonus: Discretionary target up to 40% of base salary.
- Equity Grant: Option to purchase 200,000 shares at an exercise price of $0.8151 per share.
- Vesting: 25% vests after one year; remainder vests monthly over 36 months.
- Severance: Eligible for 12 months of base salary and COBRA benefits upon termination without Cause or for Good Reason; full equity acceleration applies in connection with a Sale Event.
Material Changes
The filing reports a significant reduction in the company's physical footprint and a change in key financial leadership. The lease amendment reduces the company's occupancy costs and extends its lease horizon. Concurrently, Jill M. Broadfoot was appointed Chief Financial Officer, replacing Stan Blackburn, who resigned from his roles as principal financial and accounting officer effective August 15, 2018, to serve as a financial consultant.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the company's product candidates, clinical trial timelines, and funding requirements. It explicitly notes that actual results may differ materially due to risks associated with drug development, patient enrollment, and the ability to raise additional capital. No specific financial guidance or revenue outlook was provided in this report.
Investor Verification Checklist
- Verify the exact effective date of the space surrender to calculate the start of the 3% annual rent escalation.
- Confirm the total annualized rent cost post-abatement based on the 20,508 square foot footprint.
- Review the full Employment Offer Letter (Exhibit 10.1) for specific performance metrics tied to the 40% bonus target.
- Monitor the transition of financial reporting responsibilities from Stan Blackburn to Jill M. Broadfoot effective August 15, 2018.
- Assess the impact of the reduced office space on operational capacity and future hiring plans.